secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0000950170-23-022194
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q1 2023 net loss $33.2M; cash $390M; pipeline advances with Phase 3 trial plan
--------------------------------------------------------------------------------

- Net loss $33.2M ($0.22/share) vs $36.5M ($0.31/share) year ago; R&D $27.6M, G&A $9.4M.
- Cash, equivalents & marketable securities $389.7M at March 31, 2023, expected to fund into H2 2025.
- Pivotal Phase 3 SEACRAFT-2 trial for naporafenib in NRASm melanoma expected to initiate in H1 2024.
- FDA Fast Track Designation granted for ERAS-801 in glioblastoma; Phase 1 data expected H2 2023.
- Promoted Shannon Morris to CMO and Chandra Lovejoy to Chief Regulatory Affairs Officer in April 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023022194/0000950170-23-022194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023022194/eras-20230515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-022194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer